Search Results

SimBioSys and Magic Leap join forces to integrate AI-powered TumorSight Viz with AR technology, revolutionizing surgical precision and patient outcomes in cancer care.

SimBioSys announced a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

SimBioSys is pleased to announce the strategic appointment of Dr. Barry Rosen as its Chief Medical Officer.

SimBioSys announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.

SimBioSys®, a trailblazing TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine cancer precision medicine, transform patient care and defeat cancer today announced the strategic appointment of Jyoti Palaniappan as Chief Commercial Officer (CCO).

SimBioSys today it has received its first U.S. Food and Drug Administration (FDA) 510(k) clearance to market its first software application on its cloud-based digital precision medicine platform, TumorSight™.

SimBioSys, the TechBio company that combines the power of Artificial Intelligence, spatial biophysics, and data science to redefine precision medicine, transform patient care, and defeat cancer announces it will be one of the founding members of the CancerX initiative.

SimBioSys announced today it has entered a strategic collaboration with UT Southwestern to support the expansion of its PhenoScope platform, the company’s proprietary multi-modal data analysis platform which generates novel insights for discovery and clinical development, including unique spatial biophysical insights in 4-dimension space.

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.

SimBioSys ® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022.